{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T16:58:44Z","timestamp":1648918724529},"reference-count":66,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2006,2,1]],"date-time":"2006-02-01T00:00:00Z","timestamp":1138752000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Revista Espa\u00f1ola de Medicina Nuclear"],"published-print":{"date-parts":[[2006,2]]},"DOI":"10.1157\/13083351","type":"journal-article","created":{"date-parts":[[2006,6,1]],"date-time":"2006-06-01T18:39:34Z","timestamp":1149187174000},"page":"42-54","source":"Crossref","is-referenced-by-count":5,"title":["Radioinmunoterapia en los linfomas no Hodgkin: desarrollo hist\u00f3rico y estado actual"],"prefix":"10.1016","volume":"25","author":[{"given":"C.","family":"Emmanouilides","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1157\/13083351_bib1","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S0093-7754(03)00237-9","article-title":"Radioimmunotherapy in non-Hodgkin Lymphoma","volume":"30","author":"Emmanouilides","year":"2003","journal-title":"Semin Oncol"},{"key":"10.1157\/13083351_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/hyb.1999.18.1","article-title":"Milestones in the development of Lym-1 therapy","volume":"18","author":"DeNardo","year":"1999","journal-title":"Hybridoma"},{"key":"10.1157\/13083351_bib3","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1002\/ijc.2910410819","article-title":"Treatment of B cell malignancies with 1311 Lym-1 monolonal antibodies","volume":"3","author":"DeNardo","year":"1988","journal-title":"Int J Cancer Suppl"},{"key":"10.1157\/13083351_bib4","first-page":"1243","article-title":"Multicompartmental analysis of the kinetics of radioiodinated monoclonal antibody in patients with cancer","volume":"27","author":"Koizumi","year":"1986","journal-title":"J Nucl Med"},{"key":"10.1157\/13083351_bib5","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1177\/172460088700200107","article-title":"Treatment of a patient with B cell lymphoma by 1-131LYM-1 monoclonal antibodies","volume":"2","author":"DeNardo","year":"1987","journal-title":"Int J Biol Markers"},{"key":"10.1157\/13083351_bib6","first-page":"217","article-title":"Copper-67-labelled monoclonal antibody Lym-1, a potential radiopharmaceutical for cancer therapy: labeling and biodistribution in RAJI tumored mice","volume":"29","author":"Deshpande","year":"1988","journal-title":"J Nucl Med"},{"key":"10.1157\/13083351_bib7","doi-asserted-by":"crossref","first-page":"2706","DOI":"10.1002\/(SICI)1097-0142(19971215)80:12+<2706::AID-CNCR49>3.0.CO;2-D","article-title":"Increased survival associated with radiola-beled Lym-1 therapy for non-Hodgkin's lympboipa and chronic lymphocytic leukemia","volume":"80","author":"DeNardo","year":"1997","journal-title":"Cancer"},{"key":"10.1157\/13083351_bib8","first-page":"3647","article-title":"A phase I study of 90Y-2IT-BAD-Lym-l in patients with non-Hodgkin's lymphoma","volume":"20","author":"O\u2019Donnell","year":"2000","journal-title":"Anticancer Res"},{"key":"10.1157\/13083351_bib9","first-page":"2014","article-title":"A clinical trial of radioimmunotherapy with 67Cu-2IT-BAT-Lym-1 for non-Hodgkin's lymphoma","volume":"40","author":"O\u2019Donnell","year":"1999","journal-title":"J Nucl Med"},{"key":"10.1157\/13083351_bib10","first-page":"218","article-title":"Metabolism of indium chelates attached to monoclonal antibody: minimal transchelation of indium from benzyl-EDTA chelate in vivo","volume":"31","author":"Deshpande","year":"1990","journal-title":"J Nucl Med"},{"key":"10.1157\/13083351_bib11","first-page":"1317","article-title":"Factors affecting 131I-Lym-l pharmacokinetics and radiation dosimetry in patients with non-Hodgkin's lymphoma and chronic lymphocytic leukemia","volume":"40","author":"DeNardo","year":"1999","journal-title":"J Nucl Med"},{"key":"10.1157\/13083351_bib12","first-page":"1374","article-title":"Predictionof myelotoxicity using radiation doses to marrow from body, blood and marrow sources","volume":"38","author":"Lim","year":"1997","journal-title":"J Nucl Med"},{"key":"10.1157\/13083351_bib13","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1002\/(SICI)1097-0142(19971215)80:12+<2558::AID-CNCR31>3.0.CO;2-9","article-title":"Imaging for improved prediction of myelotoxicity after radioimmunotherapy","volume":"80","author":"DeNardo","year":"1997","journal-title":"Cancer"},{"key":"10.1157\/13083351_bib14","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1002\/(SICI)1097-0142(19971215)80:12+<2553::AID-CNCR30>3.0.CO;2-9","article-title":"Impact of splenomegaly on therapeutic response and I-131-LYM-1 dosimetry in patients with B-lymphocytic malignancies","volume":"80","author":"Shen","year":"1997","journal-title":"Cancer"},{"key":"10.1157\/13083351_bib15","first-page":"952","article-title":"Radiation dosimetry for 90Y-2IT-BAD-Lym-l extrapolated from pharmacokinetics using Illln-2IT-BADLym- 1 in patients with non-Hodgkin's lymphoma","volume":"41","author":"DeNardo","year":"2000","journal-title":"J Nucl Med"},{"key":"10.1157\/13083351_bib16","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1089\/cbr.1998.13.239","article-title":"Low-dose, fractionated radioimmunotherapy for B-cell malignancies using 131I-Lym-l antibody","volume":"13","author":"DeNardo","year":"1998","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1157\/13083351_bib17","doi-asserted-by":"crossref","first-page":"3246","DOI":"10.1200\/JCO.1998.16.10.3246","article-title":"Maximum-tolerated dose, toxicity, and efficacy of (131) I-Lym-1 antibody for fractionated radioimmunotherapy of non- Hodgkin's lymphoma","volume":"16","author":"DeNardo","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1157\/13083351_bib18","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1002\/cncr.10304","article-title":"Rationales, evidence, and design considerations for fractionated radioimmunotherapy","volume":"94","author":"DeNardo","year":"2002","journal-title":"Cancer"},{"key":"10.1157\/13083351_bib19","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1200\/JCO.1992.10.11.1696","article-title":"Imaging, dosimetry, and radioimmunotherapy with iodine 131-labelled anti-CD37 antibody in B-cell lymphoma","volume":"10","author":"Kaminski","year":"1992","journal-title":"J Clin Oncol"},{"key":"10.1157\/13083351_bib20","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1200\/JCO.1989.7.8.1027","article-title":"Treatment of refractory non-Hodgkin's lymphoma with radiolabeled MB-1 (anti-CD37) antibody","volume":"7","author":"Press","year":"1989","journal-title":"J Clin Oncol"},{"key":"10.1157\/13083351_bib21","first-page":"3292s","article-title":"Pharmacokinetics, dosimetry, and initial therapeutic results with 1311-and (lll)In-\/90Y-labelled humanized LL2 anti-CD22 monoclonal antibody in patients with relapsed, refractory non-Hodgkin's lymphoma","volume":"5","author":"Juweid","year":"1999","journal-title":"Clin Cancer Res"},{"key":"10.1157\/13083351_bib22","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1089\/cbr.2000.15.581","article-title":"Radioimmunotherapy in the pi-BCLl B cell lymphoma model: efficacy depends on more than targeted irradiation alone","volume":"15","author":"Illidge","year":"2000","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1157\/13083351_bib23","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/sj.leu.2402320","article-title":"Radioimmunotherapy for model B cell malignancies using 90Y-labelled anti-CD19 and anti-CD20 monoclonal antibodies","volume":"16","author":"Ma","year":"2002","journal-title":"Leukemia"},{"key":"10.1157\/13083351_bib24","first-page":"203a","article-title":"Non-myeloablative radioimmunotherapy with a Iodine-tagged anli-CD30 antibody (1311-Ki-4) in with refractory Hodgkin Lymplioma","volume":"100","author":"Schnell","year":"2002","journal-title":"Blood"},{"key":"10.1157\/13083351_bib25","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJM199308123290703","article-title":"Radioimmunotherapy of B-cell lymphoma with 111In-B1(anti-CD20) antibody","volume":"329","author":"Kaminski","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1157\/13083351_bib26","first-page":"457","article-title":"Ytirium-90-labelled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma","volume":"2","author":"Knox","year":"1996","journal-title":"Clin Cancer Res"},{"key":"10.1157\/13083351_bib27","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1172\/JCI110005","article-title":"A unique cell surface antigen identifying lymphoid malignancies of B cell origin","volume":"67","author":"Nadler","year":"1981","journal-title":"J Clin Invest"},{"key":"10.1157\/13083351_bib28","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1002\/cncr.10288","article-title":"Radionuclide-antibody conjugates for single-cell cytotoxicity","volume":"94","author":"Mattes","year":"2002","journal-title":"Cancer"},{"key":"10.1157\/13083351_bib29","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1002\/cncr.10297","article-title":"Choosing an optimal radioimmunotherapy dene for clinical response","volume":"94","author":"DeNardo","year":"2002","journal-title":"Cancer"},{"key":"10.1157\/13083351_bib30","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S1040-8428(01)00107-X","article-title":"Biodistribution and dosimetry results from a phase 111 prospectively randomised controlled trial of Zevalin radioimmunotherapy for low-grade, follicular. or transformed B-cell non-Hodgkin's lymphoma","volume":"39","author":"Wiseman","year":"2001","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1157\/13083351_bib31","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1007\/s002590000276","article-title":"Phase I\/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma","volume":"27","author":"Wiseman","year":"2000","journal-title":"Eur J Nucl Med"},{"key":"10.1157\/13083351_bib32","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1002\/cncr.10305","article-title":"Radiation dosimetry results for Zevalin radioimmunotherapy of rituximab-refractory non-Hodgkin lymphoma","volume":"94","author":"Wiseman","year":"2002","journal-title":"Cancer"},{"key":"10.1157\/13083351_bib33","first-page":"267","article-title":"Administration guidelines for radioimmunotherapy of non-Hodgkin's lymphoma with (90) Y-label led anti-CD20 monoclonal antibody","volume":"43","author":"Wagner","year":"2002","journal-title":"J Nucl Med"},{"key":"10.1157\/13083351_bib34","doi-asserted-by":"crossref","first-page":"3793","DOI":"10.1200\/JCO.1999.17.12.3793","article-title":"Phase I\/II trial of 1DECY2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma","volume":"17","author":"Witzig","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1157\/13083351_bib35","first-page":"3281s","article-title":"Radioimmunotherapy of relapsed non-Hodgkin's lymphoma with Zevalin, a 90Y-labelled anti-CD20 monoclonal antibody","volume":"5","author":"Wiseman","year":"1999","journal-title":"Clin Cancer Res"},{"key":"10.1157\/13083351_bib36","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1200\/JCO.2002.11.076","article-title":"Randomized controlled trial of yttrium-90-labelled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade,follicular, or transformed B-cell non- Hodgkin's lymphoma","volume":"20","author":"Witzig","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1157\/13083351_bib37","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.1200\/JCO.2002.11.017","article-title":"Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma","volume":"20","author":"Witzig","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1157\/13083351_bib38","doi-asserted-by":"crossref","first-page":"4336","DOI":"10.1182\/blood.V99.12.4336","article-title":"Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial","volume":"99","author":"Wiseman","year":"2002","journal-title":"Blood"},{"key":"10.1157\/13083351_bib39","first-page":"266a","article-title":"Multivariate analysis of prognostic factors correlated with response to 90-Y ibritumomab tiuxetan radioimmunotherapy for NHL","volume":"21","author":"Czuczman","year":"2002","journal-title":"Proc ASCO"},{"key":"10.1157\/13083351_bib40","first-page":"286a","article-title":"Zevalin radioimmunotherapy is safe and effective in geriatric patients with low grade, follicular or CD20 + transformed NHL","volume":"20","author":"Emmanouilides","year":"2002","journal-title":"Proc ASCO"},{"key":"10.1157\/13083351_bib41","first-page":"357a","article-title":"Zevalin radioimmunotherapy is not associated with an increase in incidence of secondary MDS or AML","volume":"100","author":"Czuczman","year":"2002","journal-title":"Blood"},{"key":"10.1157\/13083351_bib42","first-page":"227b","article-title":"Radioimmunohterapy is associated with low infectious risk","volume":"98","author":"Emmanouilides","year":"2002","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1157\/13083351_bib43","first-page":"346","article-title":"Rapid immune reconstitution after Zevalin is associated with low infectious risk","volume":"3","author":"Emmanouilides","year":"2002","journal-title":"The Hematology J"},{"key":"10.1157\/13083351_bib44","doi-asserted-by":"crossref","first-page":"202","DOI":"10.3816\/CLM.2004.n.028","article-title":"Antilymphoma treatments given subsequent to Yttrium 90 ibritumomab tiuxetan are feasible in patients with progressive non-Hodgkin's lymphoma: a review of the literature","volume":"5","author":"Ansell","year":"2004","journal-title":"Clin Lymphoma"},{"key":"10.1157\/13083351_bib45","first-page":"21","article-title":"Rituximab administration subsequent to ibritumomab tiuxetan radioimmunotherapy","author":"Saleh","year":"2002","journal-title":"Proc ASCO"},{"key":"10.1157\/13083351_bib46","first-page":"1198","article-title":"Radiation exposure is very low to patient family members following Zevalin Yttrium-90 anti-CD20 monoclonal antibody therapy for lymphoma","volume":"28","author":"Wiseman","year":"2001","journal-title":"Eur J Nucl Med"},{"key":"10.1157\/13083351_bib47","first-page":"266a","article-title":"90Y ibritumomab tiuxetan in aggressive NHL Analysis of response and toxicity","volume":"21","author":"Gordon","year":"2002","journal-title":"Proc ASCO"},{"key":"10.1157\/13083351_bib48","unstructured":"Morschauser, et al. ASH. 2004. Abs 130."},{"key":"10.1157\/13083351_bib49","first-page":"241b","article-title":"Successful treatment of Waldenstrom's macroglobulinemia with Zevalin-based therapy","volume":"98","author":"Emmanouilides","year":"2001","journal-title":"Blood"},{"key":"10.1157\/13083351_bib50","first-page":"254b","article-title":"Safety and efficacy of Zevalin in four patients with MALT lymphoma","volume":"11","author":"Witzig","year":"2001","journal-title":"Blood"},{"key":"10.1157\/13083351_bib51","first-page":"358a","article-title":"Yttrium-90 Zevalin phase I sequential dose radioimmunotherapy trial of patients with relapsed low grade and follicular B-cell NHL","volume":"100","author":"Wiseman","year":"2002","journal-title":"Blood"},{"key":"10.1157\/13083351_bib52","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2004.22.14_suppl.6519","article-title":"Phase II trial of rituximab and short duration chemotherapy followed by 90Y-ibritumomab tiuxetan as first line treatment for patients with follicular lymphoma","author":"Shipley","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1157\/13083351_bib53","first-page":"182a","article-title":"A phase I\/I I trial of high dose chemotherapy with Zevalin in combination with high-dose etoposide and cyclophosphamide followed by ASCT in patients with poor-risk or relapsed NHL","volume":"100","author":"Nademanee","year":"2002","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1157\/13083351_bib54","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.3816\/CLM.2004.s.005","article-title":"Combining yttrium 90-labeled ibritumomab tiuxetan with high-dose chemotherapy and stem cell support in patients with relapsed non-Hodgkin's lymphoma","volume":"5","author":"Winter","year":"2004","journal-title":"Clin Lymphoma"},{"key":"10.1157\/13083351_bib55","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1200\/JCO.1996.14.7.1974","article-title":"lodine-131-anti-Bl radioimmunotherapy for B-cell lymphoma","volume":"14","author":"Kaminski","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1157\/13083351_bib56","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1182\/blood.V96.4.1259","article-title":"Radioimmunotherapy with iodine (131)1 tositumomab for relapsedor refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience","volume":"96","author":"Kaminski","year":"2000","journal-title":"Blood"},{"key":"10.1157\/13083351_bib57","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1200\/JCO.2000.18.6.1316","article-title":"study of iodine-131 tositumomab for chemotherapy-re-lapsed\/refractory low-grade and transformed low-gradeB-cell non-Hodgkin's lymphomas","volume":"18","author":"Vose","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1157\/13083351_bib58","first-page":"357a","article-title":"Rituximab treatment failures: tositumomab and iodine I 131 tositumomab can produce meaningful durable response","volume":"100","author":"Horning","year":"2002","journal-title":"Blood"},{"key":"10.1157\/13083351_bib59","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1056\/NEJMoa041511","article-title":"131I-tositumomab therapy as initial treatment for follicular lymphoma","volume":"352","author":"Kaminski","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1157\/13083351_bib60","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.1182\/blood.V99.9.3158","article-title":"High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma","volume":"99","author":"Gopal","year":"2002","journal-title":"Blood"},{"key":"10.1157\/13083351_bib61","doi-asserted-by":"crossref","first-page":"2934","DOI":"10.1182\/blood.V96.9.2934","article-title":"A phase I\/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas","volume":"96","author":"Press","year":"2000","journal-title":"Blood"},{"key":"10.1157\/13083351_bib62","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1200\/JCO.2001.19.19.3918","article-title":"Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas","volume":"19","author":"Kaminski","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1157\/13083351_bib63","first-page":"335a","article-title":"Incidence of MDS and AML in patients with low grade NHL treated with Bexxar","volume":"98","author":"Bennett","year":"2001","journal-title":"Blood"},{"key":"10.1157\/13083351_bib64","first-page":"1230","article-title":"Nonmyeloablative iodine-131 anti-Bl radioimmunotherapy as outpatient therapy","volume":"39","author":"Gates","year":"1998","journal-title":"J Nucl Med"},{"key":"10.1157\/13083351_bib65","first-page":"354","article-title":"A practical methodology for patient release after tositumomab and (131)I-tositumomab therapy","volume":"43","author":"Siegel","year":"2002","journal-title":"J Nucl Med"},{"key":"10.1157\/13083351_bib66","first-page":"907","article-title":"Outpatient treatment with (131)I-anti-Bl antibody: radiation exposure to family members","volume":"42","author":"Rutar","year":"2001","journal-title":"J Nucl Med"}],"container-title":["Revista Espa\u00f1ola de Medicina Nuclear"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0212698206750121?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0212698206750121?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,15]],"date-time":"2020-04-15T05:52:32Z","timestamp":1586929952000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0212698206750121"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,2]]},"references-count":66,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,2]]}},"alternative-id":["S0212698206750121"],"URL":"https:\/\/doi.org\/10.1157\/13083351","relation":{},"ISSN":["0212-6982"],"issn-type":[{"value":"0212-6982","type":"print"}],"subject":[],"published":{"date-parts":[[2006,2]]}}}